nach oben

Current Cardiovascular Imaging Reports

Erschienen in:

01.02.2012 | Cardiac Molecular Imaging (F Jaffer, Section Editor)

Magnetic Resonance Molecular Imaging of Plaque Angiogenesis

verfasst von: Patrick M. Winter, Michael D. Taylor

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Neovascular expansion of the vasa vasorum is an early pathological biomarker of atherosclerosis, preceding endothelial dysfunction. Plaque angiogenesis accompanies intraplaque hemorrhage and plaque rupture, precursors of myocardial infarction and stroke. Molecular imaging of angiogenesis aims to map the expression of neovascular biomarkers on a cellular scale, often utilizing paramagnetic or superparamagnetic MRI contrast agents in order to generate sufficient image enhancement. Both clinically approved extracellular contrast agents and experimental targeted nanoparticles have demonstrated MRI signal enhancement that is proportional to the neovascular density in the vessel wall. Furthermore, targeted contrast agents formulated with anti-angiogenic drugs can be used to quantify drug deposition within the plaque and predict subsequent therapeutic effects. Molecular imaging of plaque angiogenesis has shown promise for interrogating the pathophysiology of atherosclerotic lesions rather than just their physical characteristics, with the ultimate goal of identifying the high-risk plaques that are most likely to cause cardiovascular events.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801–9. doi:10.1038/362801a0.PubMedCrossRef

Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes Jr DR, Richardson DM, Ritman EL, et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res. 2001;51(4):762–6.PubMedCrossRef

Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218(1):7–29. doi:10.1002/path.2518.PubMedCrossRef

Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13–8. doi:10.1016/j.jacc.2005.10.065.PubMedCrossRef

Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther. 2005;3(4):705–15. doi:10.1586/14779072.3.4.705.PubMedCrossRef

Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM. Emerging nanomedicine opportunities with perfluorocarbon nanoparticles. Expert Rev Med Devices. 2007;4(2):137–45. doi:10.1586/17434440.4.2.137.PubMedCrossRef

Sosnovik DE. Molecular imaging in cardiovascular magnetic resonance imaging: current perspective and future potential. Top Magn Reson Imaging. 2008;19(1):59–68. doi:10.1097/RMR.0b013e318176c57b.PubMedCrossRef

Botnar RM, Buecker A, Wiethoff AJ, Parsons Jr EC, Katoh M, Katsimaglis G, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110(11):1463–6. doi:10.1161/01.CIR.0000134960.31304.87.PubMedCrossRef

Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109(16):2023–9. doi:10.1161/01.CIR.0000127034.50006.C0.PubMedCrossRef

10.

Katoh M, Haage P, Wiethoff AJ, Gunther RW, Bucker A, Tacke J, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44(3):146–50. doi:10.1097/RLI.0b013e318195886d.PubMedCrossRef

11.

Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008;130(18):6025–39. doi:10.1021/ja800834y.PubMedCrossRef

12.

Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005;112(3):396–9. doi:10.1161/CIRCULATIONAHA.104.529941.PubMedCrossRef

13.

Spuentrup E, Katoh M, Buecker A, Fausten B, Wiethoff AJ, Wildberger JE, et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42(8):586–95. doi:10.1097/RLI.0b013e31804fa154.PubMedCrossRef

14.

Spuentrup E, Katoh M, Wiethoff AJ, Parsons Jr EC, Botnar RM, Mahnken AH, et al. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med. 2005;172(4):494–500. doi:10.1164/rccm.200503-379OC.PubMedCrossRef

15.

• Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol 2009;44(11):697–704. doi:10.1097/RLI.0b013e3181b092a7. This paper reports the clinical utility of a MR molecular imaging agent for detecting thrombi. PubMedCrossRef

16.

Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126(50):16316–7. doi:10.1021/ja044911a.PubMedCrossRef

17.

Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med. 2006;56(3):601–10. doi:10.1002/mrm.20995.PubMedCrossRef

18.

Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation. 2004;109(23):2890–6. doi:10.1161/01.CIR.0000129310.17277.E7.PubMedCrossRef

19.

Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107(19):2453–8. doi:10.1161/01.CIR.0000068315.98705.CC.PubMedCrossRef

20.

Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103(3):415–22.PubMed

21.

Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000;35(8):460–71.PubMedCrossRef

22.

Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol. 2002;37(7):405–11.PubMedCrossRef

23.

Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14(4):355–61. doi:10.1002/jmri.1194.PubMedCrossRef

24.

U-King-Im JM, Trivedi RA, Graves MJ, Cross JJ, Horsley J, Goddard MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35(7):1631–5. doi:10.1161/01.STR.0000131268.50418.b7.PubMedCrossRef

25.

Arbab AS, Jordan EK, Wilson LB, Yocum GT, Lewis BK, Frank JA. In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther. 2004;15(4):351–60. doi:10.1089/104303404322959506.PubMedCrossRef

26.

Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 2004;104(4):1217–23. doi:10.1182/blood-2004-02-0655.PubMedCrossRef

27.

Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med. 1998;40(2):236–42.PubMedCrossRef

28.

Modo M, Mellodew K, Cash D, Fraser SE, Meade TJ, Price J, et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage. 2004;21(1):311–7.PubMedCrossRef

29.

Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med. 2000;6(3):351–5. doi:10.1038/73219.PubMedCrossRef

30.

Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov Jr A. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem. 2002;13(1):122–7.PubMedCrossRef

31.

Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz Jr JD, et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods. 2001;256(1–2):89–105.PubMedCrossRef

32.

Koch AM, Reynolds F, Kircher MF, Merkle HP, Weissleder R, Josephson L. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem. 2003;14(6):1115–21. doi:10.1021/bc034123v.PubMedCrossRef

33.

Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18(4):410–4. doi:10.1038/74464.PubMedCrossRef

34.

Schellenberger EA, Bogdanov Jr A, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 2002;1(2):102–7.PubMedCrossRef

35.

Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114(14):1504–11. doi:10.1161/CIRCULATIONAHA.106.646380.PubMedCrossRef

36.

Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12(1):56–62. doi:0735-1097(88)90356-7.PubMedCrossRef

37.

Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78(5 Pt 1):1157–66.PubMedCrossRef

38.

Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657–71.PubMed

39.

Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev. 2009;3(2):91–107. doi:10.2174/157340507780619179.PubMedCrossRef

40.

Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 2005;112(22):3437–44. doi:10.1161/CIRCULATIONAHA.104.528174.PubMedCrossRef

41.

Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002;15(1):62–7. doi:10.1002/jmri.10030.PubMedCrossRef

42.

Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation. 2003;107(6):851–6.PubMedCrossRef

43.

• Kerwin WS, Oikawa M, Yuan C, Jarvik GP, Hatsukami TS. MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med 2008;59(3):507–14. doi:10.1002/mrm.21532. This paper reports clinical dynamic contrast-enhanced MRI for evaluating plaque angiogenesis in the carotid arteries. PubMedCrossRef

44.

Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;63(18):5838–43.PubMed

45.

Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, et al. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008;22(8):2758–67. doi:10.1096/fj.07-103929.PubMedCrossRef

46.

•• Cai K, Caruthers SD, Huang W, Williams TA, Zhang H, Wickline SA, et al. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging 2010;3(8):824–32. doi:10.1016/j.jcmg.2010.03.012. This paper reports serial MR molecular imaging of aortic angiogenesis in a diabetic rat model and the anti-angiogenic effects of an appetite-suppressant drug. PubMedCrossRef

47.

Neubauer AM, Sim H, Winter PM, Caruthers SD, Williams TA, Robertson JD, et al. Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med. 2008;60(6):1353–61. doi:10.1002/mrm.21795.PubMedCrossRef

48.

•• Winter PM, Caruthers SD, Allen JS, Cai K, Williams TA, Lanza GM, et al. Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med 2010;64(2):369–76. doi:10.1002/mrm.22447. This paper reports MR molecular imaging for monitoring the therapeutic effects of a pro-angiogenic drug in an animal model of peripheral vascular disease. PubMed

49.

•• Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging 2008;1(5):624–34. doi:10.1016/j.jcmg.2008.06.003. This paper reports the first use of serial MRI to monitor the anti-angiogenic effects of oral statin and a targeted anti-vascular therapy in atherosclerosis. PubMedCrossRef

50.

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108(18):2270–4. doi:10.1161/01.CIR.0000093185.16083.95.PubMedCrossRef

51.

Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(9):2103–9. doi:10.1161/01.ATV.0000235724.11299.76.PubMedCrossRef

52.

Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99(13):1726–32.PubMed

53.

Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Canc J Int Canc. 1996;68(3):397–405. doi:10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4.CrossRef

54.

Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997;15(12):1271–5. doi:10.1038/nbt1197-1271.PubMedCrossRef

55.

Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95(12):1225–33. doi:10.1161/01.RES.0000150373.15149.ff.PubMedCrossRef

56.

Moreno PR, Purushothaman K-R, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation. 2006;113(18):2245–52. doi:10.1161/CIRCULATIONAHA.105.578955.PubMedCrossRef

57.

Hamada Y, Gonda K, Takeda M, Sato A, Watanabe M, Yambe T, et al. In vivo imaging of the molecular distribution of the VEGF receptor during angiogenesis in a mouse model of ischemia. Blood 2011. doi:10.1182/blood-2010-12-322842.

58.

Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci. 2011;102(1):117–21. doi:10.1111/j.1349-7006.2010.01763.x.PubMedCrossRef

59.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med: Official Publication, Society of Nuclear Medicine. 2010;51(5):761–7. doi:10.2967/jnumed.109.071043.CrossRef

60.

Fischer T, Thomas A, Tardy I, Schneider M, Hünigen H, Custodis P, et al. Vascular endothelial growth factor receptor 2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model. Invest Radiol. 2010;45(10):675–84. doi:10.1097/RLI.0b013e3181efd6b2.PubMedCrossRef

61.

Anderson CR, Rychak JJ, Backer M, Backer J, Ley K, Klibanov AL. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol. 2010;45(10):579–85. doi:10.1097/RLI.0b013e3181efd581.PubMedCrossRef

62.

Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging. 2011;29(5):587–600. doi:10.1016/j.mri.2011.02.003.PubMedCrossRef

63.

Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol. 2009;193(2):304–13. doi:10.2214/AJR.09.2869.PubMedCrossRef

64.

He T, Smith N, Saunders D, Doblas S, Watanabe Y, Hoyle J, et al. Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. J Cell Mol Med. 2011;15(4):837–49. doi:10.1111/j.1582-4934.2010.01091.x.PubMedCrossRef

65.

Liu Y, Chen Z, Liu C, Yu D, Lu Z, Zhang N. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials. 2011;32(22):5167–76. doi:10.1016/j.biomaterials.2011.03.077.PubMedCrossRef

66.

Towner RA, Smith N, Asano Y, He T, Doblas S, Saunders D, et al. Molecular magnetic resonance imaging approaches used to aid in the understanding of angiogenesis in vivo: implications for tissue engineering. Tissue Eng Part A. 2010;16(2):357–64. doi:10.1089/ten.TEA.2009.0233.PubMedCrossRef

67.

Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 2011;31(6):2283–90.PubMed

68.

Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4(1):32–42.PubMed

Titel: Magnetic Resonance Molecular Imaging of Plaque Angiogenesis
verfasst von: Patrick M. Winter
Michael D. Taylor
Publikationsdatum: 01.02.2012
Verlag: Current Science Inc.
Erschienen in: Current Cardiovascular Imaging Reports / Ausgabe 1/2012
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-011-9121-5

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Molecular MRI of Inflammation in Atherosclerosis

Molecular Imaging of Macrophages in Atherosclerosis

FDG-PET-CT as a Biomarker for Aortic Valve Inflammation

Molecular MRI of Atherosclerosis Burden